Soligenix Targets Bundibugyo Ebola Vaccine Funding Amid Ongoing Outbreak
Event summary
- Soligenix applying for CEPI funding for Bundibugyo Ebola vaccine by June 12, 2026.
- ThermoVax® platform demonstrated thermostability and 100% protection in non-human primates for related filoviruses.
- Ongoing Bundibugyo outbreak in DRC and Uganda has 397 confirmed cases and 65 deaths as of June 4, 2026.
- CEPI has $3.6 billion in committed investments with 470 global partners.
The big picture
Soligenix's application for Bundibugyo vaccine funding comes amid a declared global health emergency, highlighting the urgent need for thermostable vaccines in outbreak-prone regions. The company's ThermoVax® platform positions it as a competitor in the filovirus vaccine space, where existing solutions require stringent cold-chain storage. CEPI's $3.6 billion investment pool underscores the global priority of epidemic preparedness, with Soligenix potentially benefiting from this strategic focus.
What we're watching
- Funding Success
- Whether Soligenix secures CEPI funding to advance Bundibugyo vaccine development.
- Thermostability Advantage
- How the ThermoVax® platform's thermostability could enhance vaccine distribution in endemic regions.
- Outbreak Containment
- The pace at which the Bundibugyo outbreak spreads and the impact on vaccine demand.